Obsessive Compulsive Treatment Efficacy Trial (OCTET) comparing the clinical and cost effectiveness of self-managed therapies: study protocol for a randomised controlled trial by Gellatly, Judith et al.
TRIALS
Gellatly et al. Trials 2014, 15:278
http://www.trialsjournal.com/content/15/1/278STUDY PROTOCOL Open AccessObsessive Compulsive Treatment Efficacy
Trial (OCTET) comparing the clinical and cost
effectiveness of self-managed therapies: study
protocol for a randomised controlled trial
Judith Gellatly1*, Peter Bower2, Dean McMillan3, Christopher Roberts4, Sarah Byford3, Penny Bee1, Simon Gilbody3,
Catherine Arundel3, Gillian Hardy5, Michael Barkham5, Shirley Reynolds6, Lina Gega7, Patricia Mottram8,
Nicola Lidbetter9, Rebecca Pedley1, Emily Peckham3, Janice Connell10, Jo Molle11, Neil O’Leary4 and Karina Lovell1Abstract
Background: UK National Institute of Health and Clinical Excellence guidelines for obsessive compulsive disorder
(OCD) specify recommendations for the treatment and management of OCD using a stepped care approach. Steps
three to six of this model recommend treatment options for people with OCD that range from low-intensity guided
self-help (GSH) to more intensive psychological and pharmacological interventions. Cognitive behavioural therapy
(CBT), including exposure and response prevention, is the recommended psychological treatment. However, whilst
there is some preliminary evidence that self-managed therapy packages for OCD can be effective, a more robust
evidence base of their clinical and cost effectiveness and acceptability is required.
Methods/Design: Our proposed study will test two different self-help treatments for OCD: 1) computerised CBT (cCBT)
using OCFighter, an internet-delivered OCD treatment package; and 2) GSH using a book. Both treatments will be
accompanied by email or telephone support from a mental health professional. We will evaluate the effectiveness,
cost and patient and health professional acceptability of the treatments.
Discussion: This study will provide more robust evidence of efficacy, cost effectiveness and acceptability of self-help
treatments for OCD. If cCBT and/or GSH prove effective, it will provide additional, more accessible treatment options
for people with OCD.
Trial registration: Current Controlled Trials: ISRCTN73535163. Date of registration: 5 April 2011
Keywords: Obsessive compulsive disorder, Guided self-help, Computerised cognitive behaviour therapy, Cognitive
behaviour therapy, Exposure and response preventionBackground
Obsessive compulsive disorder (OCD) is a chronic and
disabling mental health condition which exhibits a chronic
course unless adequately treated [1]. The obsessions and
compulsions that characterise this disorder lead to marked
distress, are time consuming and significantly interfere
with an individual's functioning. OCD affects approxi-
mately 1.1 to 3.0% of the population [2,3].* Correspondence: judith.l.gellatly@manchester.ac.uk
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unless otherwise stated.National Institute of Health and Clinical Excellence
(NICE) guidelines for OCD [4] recommend the manage-
ment of OCD using a stepped care approach [5]. Stepped
care is viewed as a potential solution to overcoming poor
access to traditional treatments by increasing the effi-
ciency of service provision and benefit to patients. Steps 3
to 6 recommend treatment options for people with OCD
that range from low-intensity, primary care-led guided
self-help (GSH) to more intensive psychological and
pharmacological interventions. Cognitive behavioural
therapy (CBT) including exposure response prevention
(ERP) is the recommended psychological treatment.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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NICE OCD guidelines as less than 10 hours of therapist
time and include CBT (including ERP) with self-managed
materials and brief individual CBT by telephone. NICE
did not recommend computerised CBT (cCBT) as a treat-
ment, as evidence for cCBT is more limited. A systematic
review [6] of cCBT for OCD found only four studies, all
using the commercially produced software programme
OCFighter (previously known as BT Steps; CCBT Limited,
Birmingham, UK (www.ccbt.co.uk)), which found that
OCFighter showed some benefit in reduction of symp-
toms and improved work and social functioning. Over-
all, therapist-delivered CBT was more effective than
OCFighter. Although there is some preliminary evidence
that self-managed therapy packages for OCD can be
effective, a more robust evidence base of efficacy, cost
effectiveness and acceptability framed within UK National
Health Service (NHS) services is required.
Our study aims to determine: 1) the clinical and cost
effectiveness of two self-managed CBT interventions
(cCBT and GSH) compared to a CBT waiting list in the
management of adults with OCD in the short term at
3- and 6-month follow-up; 2) the clinical and cost effect-
iveness of self-managed therapies plus conventional
CBT compared to waiting list plus conventional CBT at
12-month follow-up; and 3) patient compliance and
patient and health professional acceptability of the two
self-managed therapy packages (cCBT and GSH).Methods
Design
This study is a multi-centre randomised controlled trial
to evaluate the clinical and cost effectiveness of two self-
help packages compared to waiting list control for CBT.
Informed consent will be obtained from each participant;
those who are eligible will be individually randomised to
one of three arms: 1) a commercially produced cCBT
programme (OCFighter); 2) GSH; or 3) a waiting list for
conventional therapist-led CBT.
An internal pilot was conducted to explore the validity
of recruitment. This phase of the Obsessive Compulsive
Treatment Efficacy Trial (OCTET) was conducted over
the first nine months of the recruitment phase and was
designed to assess three questions relating to the main
trial: 1) is it feasible to recruit the numbers required for
a fully powered trial in the designated recruitment time
available? 2) Do participants remain on a CBT waiting
list for a sufficient length of time (that is, at least
3 months) to conduct an evaluation of the short-term
clinical and cost effectiveness of self-managed therap-
ies? and 3) Is it feasible to retain the proposed 6-month
outcome as the primary assessment for short term clin-
ical effectiveness?The pilot was successful and provided evidence that
recruitment to target was feasible. At the end of the
pilot phase it was identified that it was not feasible to
use the proposed 6-month follow-up as the primary
outcome assessment, as a significant minority of patients
had already reached the top of the waiting list before start-
ing or completing the OCTET interventions. A decision
to retain the 3-month assessment as the primary outcome
assessment was made.
Randomised controlled trial
A multi-centre fully randomised controlled trial will be
conducted to evaluate two self-managed packages (cCBT
and GSH) compared to a waiting list prior to therapist-
based CBT.
The key objectives of the OCTET trial are to determine:
1) the clinical and cost effectiveness of two self-managed
CBT interventions (cCBT and GSH) compared to a CBT
waiting list in the management of OCD patients in the
short term at 3- and 6-month follow-up; 2) the clinical
and cost effectiveness of self-managed therapies plus
conventional CBT compared to waiting list plus conven-
tional CBT at 12-month follow-up; and 3) acceptability of
the two self-managed therapy packages (cCBT and GSH)
among patients and professionals.
We will randomise patients to: 1) cCBT; 2) GSH; or 3)
CBT waiting list. The primary outcome will be OCD
symptoms as measured by the Yale Brown Obsessive
Compulsive Scale (YBOCS) observer-report version [7].
Table 1 details the secondary outcomes and the tools
that will be used.
Three-month follow-up
The 3-month follow-up, as established in the pilot, is the
agreed primary outcome point. The primary outcome
point reflects CBT waiting lists, and as such will enable
us to determine an estimate of short-term clinical and
cost effectiveness of the two self-managed therapy pack-
ages compared to a CBT waiting list control. This design
will not require patients within the trial to have restricted
access to treatment beyond that already associated with
resource limitations at each site.
Twelve-month follow-up
At 12 month follow-up we would expect participants
randomised to the waiting list to have been provided
with access to conventional CBT. Participants rando-
mised to one of the self-managed packages (either cCBT
or GSH) are expected to have either remained on the
waiting list and been provided with access to conventional
CBT or improved sufficiently with the self-managed pack-
age that they no longer require conventional CBT.
The 12-month follow-up will enable us to provide a prag-
matic demonstration of the clinical and cost effectiveness
Table 1 Secondary outcome measures
Secondary outcomes Measured using/by
Self-reported health-related
quality of life
The Short Form (36) Health
Survey (SF-36) [8]
Self-reported OCD symptoms YBOCS self-rated [7]
Generic mental health Clinical Outcomes in Routine
Evaluation (CORE-OM) [9]
Depression Patient Health Questionnaire
(PHQ-9) [10]
Anxiety Generalised Anxiety Disorder
7 (GAD-7) [11]
Functioning Work and Social Adjustment
Scale (WSAS) [12]
Health-related quality of life EuroQoL (EQ5D) [13]
Employment status IAPT Employment Status
questions A13–A15 [14]
Patient satisfaction Client Satisfaction Questionnaire
(CSQ-8 UK) [15]
Attachment Relationship Styles
Questionnaire (RSQ) [16]
Perceived criticism Perceived Criticism Scale
(PCS) [17]
Expressed emotion Family Emotional Involvement
and Criticism Scale (FEICS) [18]
Patient progression through mental
health services/proportion of patients
not improved or partially improved
and requiring more intensive CBT
‘Pathway Questionnaire’
Patient and therapist acceptability Qualitative interviews
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versus waiting list followed by conventional CBT in the
longer term. We will be able to explore patterns of
longer term outcomes: 1) do patients who access self-
managed therapies improve in the short term but
relapse in the longer term? 2) Does provision of self-
managed therapies augment the benefit from conventional
CBT? 3) Do patients who access self-managed therapies
maintain longer term outcomes and have less need for
conventional CBT than those who remain on a waiting list
prior to being offered conventional CBT?
These results will provide critical information concern-
ing the longer term role of self-managed therapy packages
for OCD compared to usual care with conventional CBT.
Inclusion/exclusion criteria
Inclusion
Our target population will be adults aged 18 years and
above who: meet Diagnostic and Statistical Manual of
Mental Disorders (DSM) IV criteria for OCD (assessed
using Structured Clinical Interview for DSM (SCID)-IV
[19]); score 16 or over on the YBOCS [7] (clinical experi-
ence and previous studies suggest that only a minority of
people are referred for treatment or excluded from trialswith a YBOCS less than 16 (for example, 2.3% [20] 0%
[21], 14% [22]); are on a waiting list for therapist-led
CBT in either primary or secondary mental healthcare
settings; have the ability to read English at a level of
11 years and above.
Exclusion
We will exclude patients who: are actively suicidal; have
organic brain disease; are experiencing psychosis; meet
DSM VI criteria for drug or alcohol dependence [23];
are currently receiving a psychological treatment for
OCD; have received CBT for OCD in the last 6 months;
have literacy or language difficulties to an extent which
would preclude them from reading written or web-based
materials or conversing with a health professional.
Patients who have been prescribed or changed to an
alternative anti-depressant in the 12 weeks prior to as-
sessment will be excluded, though these patients will be
offered a further assessment following 12 weeks of
stable medication if there are no plans to increase the
medication.
Recruitment
We will screen all waiting lists in primary and secondary
care in our clinical sites and invite potentially eligible
participants to a telephone eligibility screen. We will
also apply for adoption by the Mental Health Research
Network and link with the Primary Care Research Network.
These networks, part of the National Institute of Health
Research (NIHR), are dedicated to support mental health
research projects so we can identify ways in which NHS
healthcare can be improved and to ensure maximum
patient benefit. They will assist with recruitment from clin-
ical sites to ensure that we fulfil our recruitment target.
If a participant meets the eligibility screen the researcher
will give further details of the trial, send information
leaflets and a consent form by post and offer them a
face-to-face appointment (either in the clinical site or
their own home) within seven days from the telephone
screen. At the face-to-face interview consent and baseline
measures will be taken.
We will recruit a minimum of 432 patients (assuming a
15% attrition rate, total n = 368). Recruitment will occur
over a 27-month recruitment period (including the 9-
month pilot phase). A £5.00 shopping voucher will be
given to each participant completing 3, 6 and 12 months
follow-up assessments.
Randomisation
Patients will be randomised into one of the three arms
of the trial: 1) cCBT; 2) GSH; or 3) CBT waiting list.
To ensure the removal of selection bias, allocation will
be concealed from the researchers completing assess-
ments by randomisation through a central randomisation
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senting patients will be entered onto a secure web-based
system administered by the Clinical Trials Unit, which will
then provide the treatment allocation. Allocation involves
minimisation on three important factors - OCD severity
(moderate/severe) measured by self-rated YBOCS, anti-
depressant medication (yes/no) and depression (mild/mod-
erate/severe) measured by PHQ-9 - with the aim of ensur-
ing a balance across treatment arms.
To reduce detection bias, we will aim to blind researchers
undertaking outcome assessments to participants’ treat-
ment allocation. To facilitate blinding, we will use the
following procedures: 1) ensuring that the outcome
assessments conducted by researchers are completed on
different days or locations from the clinical areas in which
treatment is being conducted; and 2) asking participants
to refrain from revealing their treatment allocation at
follow-up assessments. Finally we will test blinding by
asking researchers to guess the treatment allocation of
the patient at each follow-up and to record the number
of patients who inadvertently reveal their treatment
allocation.
Sample size
In trials of non-pharmacological interventions it is
recommended that variation between care-providers is
considered in sample size estimation and statistical
analysis [24]. In this trial there could be variation by
therapist (mental health practitioners) in the two self-
managed therapies. For the comparisons of CBT waiting
list with cCBT or GSH we have assumed between-therapist
variation in the active treatment corresponding to a
partially-nested design. For the comparison of cCBT
versus GSH the same set of therapists will “supervise”
both interventions so the trial is therefore a cross-design
[25]. Sample size is estimated using the methods described
by Walwyn and Roberts [25].
We are not aware of directly relevant estimates for
intra-cluster correlation coefficient (ICC) between treat-
ments within therapists, which would be required for
sample size estimation for comparison (i) self-managed
therapy packages (cCBT versus GSH). We are also not
aware of estimates for the ICC for therapists, necessary
for sample size estimation for comparisons (ii) CBT
waiting list versus cCBT and (iii) CBT waiting list versus
GSH. We expect the ICC between treatments within
therapists to be less than half the ICC between therapists.
With a total sample size of 432 clients and 24 therapists
(average of six therapists per clinical site) each with a
caseload of six cCBT and six GSH clients the trial will
have a power greater than 80% to detect a difference of
3 YBOCS points for each comparison provided the ICC
for therapists does not exceed 0.06 and the ICC for
treatment within therapists does not exceed 0.015. Thiscalculation assumes a 85% follow-up rate to 3 months
(87% was achieved within Lovell and colleagues [20]), a
1.67% significance level to maintain a 5% significance
level for three pair-wise comparisons, SD for the primary
outcome YBOCS at 3 months of 7.3 units, and a correl-
ation between baseline YBOCS and 3 months YBOCS of
0.43 [20]. In the event that the ICC for therapists is less
than 0.1 and the ICC for treatment within therapists is less
than 0.05 (which would represent unexpectedly large
values), the power is still greater than 75%. By virtue of
involving a comparatively large number of therapists
the trial is therefore robust against larger ICC values
for therapists.
Interventions
Experimental group 1: computerised cognitive behavioural
therapy
OCFighter is a commercially produced cCBT programme
for people with OCD. OCFighter consists of a nine-step
CBT approach (focussed on ERP). Participants randomised
to OCFighter will be given an access ID and password
to log into the system and will be advised to use the
programme at least six times over a 12-week period.
cCBT will be offered in one of three locations according
to patient choice and local availability: 1) the patients’ own
home; 2) the home of a friend or family (if they already
have a computer and a broadband connection); 3) the
CBT department in the clinical site where the patient is
on the waiting list (if a computer in a private room operat-
ing on a weekly booking system can be provided). We will
actively encourage participants to use cCBT in their own
home as the first option.
Participants will receive six, 10-minute brief scheduled
support sessions, via telephone or face-to-face (depending
on patient preference) from a mental health practitioner
(total direct clinical input 60 minutes). The support of-
fered will consist of a brief risk assessment, ensuring
that they are able to and have accessed OCFighter, review
progress and problem solve any difficulties which are
impeding progress.
Experimental group 2: guided self-help
The GSH group will consist of a self-help book written
by the authors KL and LG. Participants will receive
weekly guidance from a mental health practitioner for
one initial session of 60 minutes (either face-to-face or
via telephone dependent on patient preference) followed
by up to ten (30-minute) scheduled telephone or face-
to-face (dependent on patient preference) sessions over
a 12 week period (total direct clinical input 6 hours). The
role of the mental health practitioner will be to conduct a
semi-structured interview, devise patient-centered goals
and explain the structure and content of the book. They
will support them to use the CBT (ERP) interventions
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culties as they arise and engage in collaborative problem
solving as required.
Comparator group 3: waiting list for cognitive behavioural
therapy
Our control group will be a waiting list for conventional
therapist-led CBT (in both primary and secondary care
settings).
Training and supervision of mental health professionals
The mental health professionals supporting GSH will be
individuals who have had mental health training but do
not have specialist CBT skills.
Training will be provided for the GSH intervention by
trial applicants who have experience and expertise in
conducting CBT, GSH and cCBT. cCBT training will be
provided for OCFighter by CCBT Limited (manufacturers
of OCFighter). Training will consist of 2 days for GSH and
1 day for cCBT and will be delivered at the clinical sites.
Training will utilise a range of methods including small and
large group work and skill practice with specific feedback
using fictitious but typical cases of moderate and severe
OCD. Training manuals will be written by the trial team
and CCBT Limited and provided for both treatment arms.
Supervision will be provided on a two-weekly basis to
the mental health professionals by either clinically quali-
fied trial applicants or senior clinicians within a service.
Researchers and Clinical Study Officers involved in re-
cruitment of participants will be provided with a 1-day
extensive training session covering trial procedures and
completion of eligibility, baseline and follow-up interviews.
A proportion of the day will be spent equipping individuals
with the necessary skills to complete the clinician-rated
YBOCS. Inter-rater reliability among the researchers/
Clinical Study Officers will be employed to measure agree-
ment between ratings for the YBOCS. Top-up training will
be provided throughout the trial.
Concurrent process evaluation
Criticism has been aimed at randomised controlled trials
that only focus on pre-specified health outcomes. Process
evaluation within trials is recommended to examine key
issues such as implementation, acceptability and feasibility,
which add to the understanding of the randomised con-
trolled trial results. This study will conduct a process
evaluation to explore the barriers and facilitators of imple-
mentation by examining the extent to which: 1) patients
comply with treatment; and 2) patients and health profes-
sionals find treatment acceptable.
Patient compliance with treatment
A key aspect of any treatment is the extent to which users
complete their agreed course of treatment includingCBT between-session tasks. Treatment compliance will
be examined through recording the number of sessions
attended, and use of self-help materials. With cCBT we
will collect automated recordings of the frequency and
duration of cCBT use, and patient self-reports of time
spent between sessions doing CBT-based tasks. In the
GSH arm we will collect number, duration and mode of
contact (telephone, email or face-to-face) via mental
health practitioner records as well as patient diaries of
between-session work.
Acceptability of treatments to patients and health
professionals
Successful implementation of research into NHS practice
requires that new interventions are accepted and welcomed
by both patients and mental health professionals. Qualita-
tive interviews will be conducted post-intervention with a
subgroup of 10% of patients stratified by baseline severity
in both active intervention arms of the trial across clinical
sites. Patients will be sampled on characteristics including
gender, ethnicity and outcome. We expect to conduct
approximately 40 to 48 interviews (11 to 12 interviews
at each site). We will also conduct exit interviews with
participants who leave treatment early. A sample of 15
to 20 health professionals will be interviewed with the
aim of exploring potential barriers and facilitators to
implementing GSH and cCBT into clinical practice.
Participants will be identified from health professionals
who are working in our sites but are not treating patients
as part of our trial. The Client Satisfaction Questionnaire
will be used to compare patient satisfaction across the
treatment arms and, with other quantitative data, to
identify predictors of satisfaction.
Economic evaluation
Little evidence exists regarding the service use or costs
associated with OCD, or the cost effectiveness of alter-
native treatment strategies [26-28], with the exception of
a small number of cost of illness or costing studies
[29-31], productivity loss [32] and caregiver burden [33]
estimates. Clinical evaluations of treatment alternatives
for OCD that have included a cost or cost-effectiveness
component have been severely limited to the cost of the
interventions under evaluation, with no data collected
on the impact of the treatment options on the use of
other health and social services, patient and family costs,
or productivity losses [34-36].
The primary perspective of the economic evaluation
will be the NHS/Personal Social Services perspective
preferred by NICE. Secondary analyses will take a societal
perspective. In line with the key objectives of the proposed
trial, the following cost-effectiveness analyses will be
undertaken: 1) brief CBT (cCBT and GSH) compared
to no active intervention (that is, CBT waiting list) in
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month follow-up, as determined during the pilot phase
described previously); 2) self-managed therapies plus
usual care (waiting list plus access to therapist-led full
CBT) versus usual care alone at 12-month follow-up.
Data will be collected on the use of all hospital and
community health and social services, productivity losses
and costs to patients/families. To the best of our know-
ledge, no OCD-specific tool for measuring use of services
and other resources exists. Instead, the Adult Service Use
Schedule (AD-SUS), a generic measure developed by
author SB and successfully applied to a range of studies
of adult mental health services [37-39], was adapted for
OCD through review of relevant literature and discussions
with the clinical team to ensure it adequately captures
resources appropriate to OCD. The adapted version
was tested at baseline interviews with participants in
the pilot phase to ensure all important resources are
captured. Intervention resources will be collected from
therapist records to ensure accuracy and avoid unblinding
research assessors.
The unit cost of study interventions will be calculated
directly using established methods of micro-costing [40].
Calculations will require data on therapist salaries, includ-
ing appropriate overheads and employers’ own costs
(national insurance and superannuation), working time
and estimates of the ratio of direct face-to-face to indirect
time. The cost of cCBT will require information on the
licensing costs, plus data on any additional purchases
of equipment required. For all other health and social
services, nationally applicable unit costs will be applied
[41-43]. Productivity losses will be calculated using the
human capital approach, which involves multiplying days
off work due to illness by the individual’s salary [44].
Statistical analysis
Statistical analyses and sample size
A full statistical analysis plan for the analysis of primary
and secondary outcome measures including any sub-group
analyses will be drafted prior to the commencement of the
trial. This will be presented to the Trial Steering Committee
(TSC) and the Data Monitoring and Ethics Committee
(DMEC) and revised prior to the start of outcome data
analysis. During the recruitment and follow-up period
regular reports will be prepared for the TSC/DMEC on
data quality.
The analyses comparing treatments will be conducted
applying the principle of intention to treat. The trial
involves the comparison of three treatments and has been
powered for a Bonferroni correction for three pair-wise
comparisons. Conditional on overall significance at a 5%
level, three pair-wise comparisons are planned between:
(1) self-managed therapy packages (cCBT versus GSH); (2)
CBT waiting list and cCBT; and (3) CBT waiting listand GSH. Inferential analysis will be carried out using a
Bonferroni corrected significance level of 0.0167.
Analyses will be performed under the assumption of
data missing at random. However, high or differential
rates of missing data between treatment arms may indi-
cate a departure from this assumption and may lead to
bias. Should this arise sensitivity analyses will be carried
out using multiple imputation under a missing not at ran-
dom mechanism.
For the primary outcome and quantitative secondary
outcome measure the treatment effects at 3 and 12 months
will be estimated separately using a linear mixed model
with a random effect for therapist. To improve the effi-
ciency of the analysis the following baseline covariates will
be included in the model for the primary outcome: (1)
YBOC score at baseline; (2) anti-depressant medication
(yes or no); (3) depression (mild, moderate, or severe); (4)
gender; (5) age; and (6) duration of OCD (0 to 5 years, 6
to 10 years, or 10 years and over). Similar covariates will
be used for other quantitative measures. A logistic mixed
regression model will be used to estimate the effect of
the interventions on uptake of CBT by 3 months and
12 months adjusting for baseline severity (YBOCS).
Participants will not be excluded from outcome analyses
due to missing baseline covariate data. Where baseline
covariate data cannot be obtained, imputation involving
other baseline covariates will be used. Unless multiple
imputation is used for the analysis of outcome, missing
baseline data will imputed by single imputation following
the suggestion of White and Thompson [45].
Differences in mean costs will be analysed using standard
parametric t-tests with the validity of results confirmed
using bias-corrected, non-parametric bootstrapping (repeat
re-sampling) [46]. Despite the skewed nature of cost data,
this approach is recommended to enable inferences to
be made about the arithmetic mean [47]. Tests will be
adjusted for baseline cost, baseline YBOC score and
variables potentially predictive of outcome including
minimisation variables. Cost effectiveness will be explored
in terms of incremental cost per quality-adjusted life year,
calculated using the EuroQoL EQ-5D measure of health-
related quality of life, and using rules of dominance and
extended dominance for a three-arm comparison [48].
Non-parametric bootstrapping from the costs and effect-
iveness data will be used to generate a joint distribution of
incremental mean costs and effects for the three arms.
This will then be used to calculate the probability that
each of the treatments is the optimal choice, subject to
a range of possible maximum values (ceiling ratio) that
a decision maker might be willing to pay for a unit
improvement in outcome. Cost effectiveness acceptability
curves are presented by plotting these probabilities for a
range of possible values of the ceiling ratio [49]. These
curves are a recommended decision-making approach to
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mates of expected costs and expected effects associated
with the interventions under investigation [50].
Analysis of acceptability interviews
Acceptability interviews will be transcribed verbatim and
data will be analysed using Framework analysis [51]. An
initial coding framework will be developed and transcripts
checked against the framework to ensure that there are no
significant omissions. Codes in each interview will be
examined across individual transcripts as well as across
the entire data set and allocated to the framework. Using
aspects of the constant comparative method of analysis
broader categories using linking codes will be developed
across interviews. Data will be interpreted and analysed
within the framework to structure patients’ views about
each intervention and reasons for leaving the intervention
early.
Ethics
Ethical approval for this randomised controlled trial has
been granted by Lancaster Research Ethics Committee
11/NW/0276.
Patient and public involvement/user engagement
Service user input, involvement and dissemination of the
proposed study comes from Nicola Lidbetter (applicant),
Chief Executive of Anxiety UK. We have strong links
with Anxiety UK and currently have a number of funded
studies (including both a NIHR programme grant and an
NIHR Health Technology Assessment programme (HTA)
grant) and unfunded collaborative studies (a qualitative
study of CBT telephone acceptability for anxiety and
depression, applicants KL, PB and NL). In addition we
will also invite members of a CCBT OCD subgroup of
the Patient and Public Involvement in Research Group
in Norfolk who have agreed to be part of a consultation
group. Our service user representation will also include
assisting us in developing the interview schedules for
the acceptability interviews. We will also offer service
users training in interviewing if they wish to conduct a
proportion of the interviews and they will contribute to
the analysis of the interviews and assist in the writing
of publications. A proportion of NL’s time will be funded
through the grant. A consultancy fee will be paid to par-
ticipating members of the patient and public involvement
in the research group.
The Trial Steering Committee and Data Monitoring and
Ethics Committee
Independent supervision of the trial will be conducted
by members of the TSC. The TSC will comprise of an
independent chair who has expertise in both trials and
OCD and two other independent members including auser representative who has had lived experience with
OCD and a clinician working with people with OCD.
The principal investigator along with the trial manager
will attend and the trial statistician will be invited when
appropriate.
A DMEC will be established to assess the progress and
safety of the study. It will consist of members external to
the study team including a statistician, a clinician and an
expert in health services trials. A DMEC report template
will be devised for reporting purposes and agreed by the
DMEC committee prior to the commencement of the
study.
Forecast execution dates
The set-up of the trial commenced in September 2011
and was complete in January 2012. Recruitment of par-
ticipants from CBT waiting lists started in a number of
sites in February 2012 and will be complete in May
2014. The pilot phase ended in October 2012 at which
point recruitment to the full trial began. Follow-up
started in May 2012, and the final 12-month follow-ups will
be conducted in May 2015. Data analysis will commence
in May 2015. Training of mental health practitioners was
ongoing throughout the trial with the last training taking
place in January 2014.
Protocol changes
Since the trial commenced a number of protocol changes
have been made. These are detailed in Table 2.
Discussion
The proposed trial is being conducted to explore if the
interventions (GSH and cCBT), designed to provide more
rapid and efficient access to patients with OCD, are
effective. Once complete it will be the largest OCD
psychological therapy trial worldwide. Some barriers
have been identified that may impact upon recruitment
and completion of the trial to time.
Participant identification methods
The core recruitment method adopted is screening existing
CBT waiting lists for potentially eligible patients. These
lists were expected to be long and thus containing a large
number of patients who may be amenable to participation
in OCTET while they waited, as participation allowed
them to remain on the waiting list. Similar methods (large
scale screening patients from registers or other existing
lists of potentially eligible patients) have underpinned a
number of our successful trials with other mental health
populations.
During the initial stages of the trial set-up, the Depart-
ment of Health wrote to sites, requiring that patients
be offered more rapid access to treatment as part of the
Improving Access to Psychological Therapies (IAPT)
Table 2 Protocol changes made since the trial commenced
Aspect of trial Changes made
Inclusion/exclusion criteria Individuals no longer excluded if they have received CBT for OCD in the last 6 months
Individuals no longer excluded if they have started or changed dose of anti-depressant medication
within the last 12 weeks
Minimisation criteria Addition of chronicity to minimisation criteria (defined as duration of OCD: 0 to 5 years/6 to 10 years/
10 years and over)
Primary outcome point changed from 6 months to 3 months following pilot evaluation
Outcomes Removal of SCID-IV, replaced by Mini-international neuropsychiatric interview (M.I.N.I) and Clinical
Interview Schedule Revised (CIS-R)
Inclusion of Client Satisfaction Questionnaire (CSQ-8 UK) at 6-month follow-up
Recruitment Submission of mail shot letter to address recruitment issues
Addition of new recruitment strategies (advert for radio, press and social media)
Asking participants to wait 12 weeks for their full CBT appointment
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http://www.trialsjournal.com/content/15/1/278initiative. The effect was that many patients potentially
eligible for OCTET were ‘removed’ from the waiting list
and offered access to a ‘low-intensity’ intervention. In
many cases, these interventions were in line with current
good practice, but were not evidence based, as few were
OCD-specific or recommended by the NICE guidelines.
However, such patients were lost to the OCTET recruit-
ment procedure, significantly reducing the numbers of
potentially eligible patients who could be contacted. In
addition, the waiting list initiatives resulted in many
patients who were already participating in the trial
being offered a CBT appointment prior to the primary
outcome point.
Governance issues
Governance delays also led to delays in the commence-
ment of recruitment. On the assumption that governance
agreement should be available within 30 days of submis-
sion it was estimated that delays across sites would
approximate to 10% loss of capacity (or the equivalent of
one site in the initial stages of recruitment).
In response to these issues, which may impact upon trial
completion, decisions have been made to recruit add-
itional sites and identify new recruitment strategies such
as invitation letters being sent to all patients currently
waiting for a CBT appointment, not restricted to those
who have an indication of OCD in their NHS records.
Trial status
We are currently in the final stage of recruiting
participants.
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